Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation

This study is ongoing, but not recruiting participants.

Study NCT00375219 Information provided by Teva Pharmaceutical Industries

First Received on September 8, 2006. Last Updated on February 21, 2013 History of Changes

Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:

Conditions listed in this trial

Additional conditions recognized in this trial

More general conditions related to this trial

Interventions listed in this trial

Additional drug interventions recognized in this trial

Harringtonines
Homoharringtonine

More general drug interventions related to this trial

Sponsors listed in this trial